Open AccessThe Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ
Author(s) -
Makoto Kobayashi,
Yoshimatsu Ehama,
Suguru Hirayama
Publication year - 2022
Publication title -
open access emergency medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.408
H-Index - 14
ISSN - 1179-1500
DOI - 10.2147/oaem.s359216
Subject(s) - medicine , disseminated intravascular coagulation , sepsis , thrombomodulin , lower respiratory tract infection , gastroenterology , antithrombin , retrospective cohort study , respiratory tract , respiratory tract infections , intensive care medicine , respiratory system , heparin , platelet , thrombin
Several studies have shown that anticoagulation can improve survival outcomes in patients with sepsis-associated disseminated intravascular coagulation (DIC). A guideline from Japan in 2020 suggested two therapeutic agents for sepsis-associated DIC treatment: antithrombin (AT) replacement therapy and recombinant thrombomodulin (rTM) preparation. In 2021, our preliminary study proposed that different organs of septic infection might lead to distinct treatment outcomes following different therapies against DIC. In this study, we created a subanalysis on the influence of AT replacement therapy and rTM preparations on overall survival (OS) by comparing two causative organs: biliary and respiratory tract infections.